BG103915A - Sertraline salts and sertralin-containing batched forms with delayed release - Google Patents

Sertraline salts and sertralin-containing batched forms with delayed release

Info

Publication number
BG103915A
BG103915A BG103915A BG10391599A BG103915A BG 103915 A BG103915 A BG 103915A BG 103915 A BG103915 A BG 103915A BG 10391599 A BG10391599 A BG 10391599A BG 103915 A BG103915 A BG 103915A
Authority
BG
Bulgaria
Prior art keywords
sertraline
forms
batched
sertralin
delayed release
Prior art date
Application number
BG103915A
Other languages
Bulgarian (bg)
English (en)
Inventor
Ende Mary Am
William Curatolo
Hylar Friedman
Ravi Shanker
Scott HERBIG
Dwayne Friesen
James West
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of BG103915A publication Critical patent/BG103915A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BG103915A 1997-07-01 1999-11-23 Sertraline salts and sertralin-containing batched forms with delayed release BG103915A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5141497P 1997-07-01 1997-07-01
US5142097P 1997-07-01 1997-07-01
US5149897P 1997-07-01 1997-07-01
US5140297P 1997-07-01 1997-07-01
PCT/IB1998/000934 WO1999001121A1 (en) 1997-07-01 1998-06-15 Sertraline salts and sustained-release dosage forms of sertraline

Publications (1)

Publication Number Publication Date
BG103915A true BG103915A (en) 2000-07-31

Family

ID=27489408

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103915A BG103915A (en) 1997-07-01 1999-11-23 Sertraline salts and sertralin-containing batched forms with delayed release

Country Status (33)

Country Link
US (1) US6517866B1 (xx)
EP (1) EP0999830A1 (xx)
JP (1) JP2000514101A (xx)
KR (2) KR100446366B1 (xx)
CN (1) CN1256085C (xx)
AP (1) AP1526A (xx)
AR (2) AR015919A1 (xx)
AU (1) AU739261B2 (xx)
BG (1) BG103915A (xx)
BR (1) BR9810403A (xx)
CA (1) CA2290966C (xx)
CO (1) CO4940402A1 (xx)
DZ (1) DZ2546A1 (xx)
EA (1) EA002482B1 (xx)
HK (1) HK1026630A1 (xx)
HR (1) HRP980379B1 (xx)
HU (1) HUP0002296A3 (xx)
ID (1) ID23503A (xx)
IL (2) IL152330A0 (xx)
IS (1) IS5265A (xx)
MY (1) MY129175A (xx)
NO (1) NO996518L (xx)
NZ (2) NZ501251A (xx)
OA (1) OA11245A (xx)
PA (1) PA8454401A1 (xx)
PE (1) PE88699A1 (xx)
PL (1) PL337806A1 (xx)
SK (1) SK180499A3 (xx)
TN (1) TNSN98125A1 (xx)
TR (1) TR199903280T2 (xx)
TW (1) TWI241188B (xx)
UY (1) UY25067A1 (xx)
WO (1) WO1999001121A1 (xx)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208926A1 (en) * 1997-07-01 2004-10-21 Pfizer Inc Solubilized sertraline compositions
DK1067910T3 (da) * 1998-04-03 2004-10-04 Egalet As Komposition med styret afgivelse
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
CA2698347A1 (en) * 1999-05-20 2000-11-30 Elan Pharma International Limited Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
ATE318135T1 (de) * 1999-09-03 2006-03-15 Apbi Holdings Llc Verwendung von dapoxetin, a selektiver serotonin- aufnahme inhibitor mit schnellem wirkungseintritt,zur behandlung von sexueller dysfunction
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
MXPA02006335A (es) 1999-12-23 2002-12-13 Pfizer Prod Inc Forma de dosificacion de farmaco en capas impulsada por hidrogel.
US6620431B1 (en) * 2000-04-17 2003-09-16 Charles Signorino Shellac film coatings providing release at selected pH and method
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
JP2004507502A (ja) 2000-08-30 2004-03-11 ファイザー・プロダクツ・インク 成長ホルモン分泌促進物質のための徐放性製剤
US6482440B2 (en) * 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
SE0004671D0 (sv) 2000-12-15 2000-12-15 Amarin Dev Ab Pharmaceutical formulation
JP2002212062A (ja) * 2001-01-24 2002-07-31 Teijin Ltd 遅延放出制御組成物
EP1366758A4 (en) * 2001-02-15 2005-07-20 Sanwa Kagaku Kenkyusho Co NEW OPHTHALMIC COMPOSITIONS
NZ528957A (en) * 2001-04-18 2005-05-27 Nostrum Pharmaceuticals Inc A novel coating for a sustained release pharmaceutical composition
RU2301662C2 (ru) * 2001-07-16 2007-06-27 Астразенека Аб Фармацевтический препарат, содержащий ингибитор протонной помпы и антациды
US20040234602A1 (en) * 2001-09-21 2004-11-25 Gina Fischer Polymer release system
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
CN100408029C (zh) * 2001-09-28 2008-08-06 麦克内尔-Ppc股份有限公司 有镶嵌部分的组合剂型
US7005138B2 (en) * 2001-12-21 2006-02-28 Duramed Pharmaceuticals, Inc. Method of systematically delivering SSRIs
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US20100189797A1 (en) 2002-06-10 2010-07-29 Julien Mendlewicz Oral antidepressant formulation
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
AU2003272461A1 (en) * 2002-09-16 2004-04-30 Sepracor Inc. TREATMENT OF CNS DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPTHALENAMINE
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
CA2415154C (en) * 2002-12-24 2009-06-16 Biovail Laboratories Inc. Modified release formulations of selective serotonin re-uptake inhibitors
WO2004065348A1 (en) * 2003-01-23 2004-08-05 Pfizer Products Inc. Pharmaceutically acceptable salts of sertraline and pharmaceutical compositions thereof
CA2514061A1 (en) * 2003-02-14 2004-09-02 Combinatorx, Incorporated Combination therapy for the treatment of immunoinflammatory disorders
EP1610767B1 (en) * 2003-03-26 2011-01-19 Egalet A/S Morphine controlled release system
MXPA05010636A (es) * 2003-04-04 2005-12-12 Pharmacia Corp Comprimidos de multiparticulas preparados por compresion de liberacion oral prolongada.
CA2523158C (en) 2003-04-24 2010-11-16 Jagotec Ag Delayed release tablet with defined core geometry
JP2007502329A (ja) * 2003-05-23 2007-02-08 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド セルトラリン組成物
ATE454138T1 (de) * 2003-08-08 2010-01-15 Biovail Lab Int Srl Tablette mit modifizierter freisetzung von bupropion hydrochlorid
ZA200603502B (en) * 2003-11-04 2008-02-27 Cipla Ltd Process for the preparation of polymorphs of selective serotonin reuptake inhibitor
AR048033A1 (es) * 2004-03-12 2006-03-22 Smithkline Beecham Plc Composicion farmaceutica para moldear componentes que comprende copolimero de poli(met)acrilato, cubierta, conector o espaciador de capsula moldeado por inyeccion que tiene la composicion farmaceutica y forma de dosificacion farmaceutica de multicomponentes a partir de dicha composicion
KR100772980B1 (ko) * 2004-04-01 2007-11-02 한미약품 주식회사 메트포르민의 경구투여용 서방성 제제
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
ITMI20041295A1 (it) * 2004-06-25 2004-09-25 Cosmo Spa Composizioni farmaceutiche antimicrobiche orali
KR101052436B1 (ko) 2004-08-13 2011-07-29 베링거 인겔하임 인터내셔날 게엠베하 프라미펙솔 또는 약제학적으로 허용되는 이의 염을함유하는 연장 방출형 정제 제형, 이의 제조방법 및 이의용도
KR100920856B1 (ko) * 2004-11-30 2009-10-09 (주)아모레퍼시픽 선택적 세로토닌 재흡수 억제제의 연장방출 제제 및 그제조방법
WO2006072878A1 (en) * 2005-01-07 2006-07-13 Ranbaxy Laboratories Limited Oral dosage forms of sertraline having controlled particle size and processes for their preparation
US20080274183A1 (en) * 2005-02-04 2008-11-06 Phillip Michael Cook Thermoplastic articles containing a medicament
WO2006123364A2 (en) * 2005-03-14 2006-11-23 Sun Pharmaceutical Industries Limited Oral drug delivery system providing a coating comprising both a cellulose and a methacrylic acid derivative
CN101188999B (zh) * 2005-06-03 2012-07-18 尹格莱特股份有限公司 用于递送分散在分散介质中的活性物质的药物传递系统
US8747897B2 (en) 2006-04-27 2014-06-10 Supernus Pharmaceuticals, Inc. Osmotic drug delivery system
US7893053B2 (en) * 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
PT2049123E (pt) 2006-08-03 2013-03-06 Horizon Pharma Ag Tratamento de doença reumatóide com glucocorticóide de libertação retardada
US20100291205A1 (en) * 2007-01-16 2010-11-18 Egalet A/S Pharmaceutical compositions and methods for mitigating risk of alcohol induced dose dumping or drug abuse
NZ580972A (en) 2007-06-04 2012-02-24 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
WO2009034431A2 (en) 2007-09-10 2009-03-19 Pfizer Inc. Controlled-release dosage forms for varenicline
EP2361082A1 (en) * 2008-08-14 2011-08-31 Bar-Shalom, Daniel Coated tablets with a remaining degradation surface over the time
DE102008051572A1 (de) 2008-09-05 2010-03-11 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Herstellung von Phosphatbindern und auf diese Weise hergestellte Phosphatbinder
AU2008243202B2 (en) * 2008-11-11 2015-08-20 Cosmo Technologies Ltd Oral antimicrobial pharmaceutical compositions
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
CN102695500A (zh) 2009-11-09 2012-09-26 聚光灯技术合伙有限责任公司 多糖基水凝胶
NZ599527A (en) 2009-11-09 2014-04-30 Spotlight Technology Partners Llc Fragmented hydrogels
CA2877183A1 (en) 2012-07-06 2014-01-09 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
WO2016020936A2 (en) * 2014-07-21 2016-02-11 Patel Jayendrakumar Dasharathlal A novel oral gastroretentive pharmaceutical dosage form
CN104402705B (zh) * 2014-11-04 2017-04-12 成都理工大学 球形柠檬酸钙及其制备方法和应用
JP6455293B2 (ja) * 2015-04-21 2019-01-23 ニプロ株式会社 セルトラリン及び／又はその薬学上許容しうる塩を含む製剤
ES2904834T3 (es) * 2017-10-05 2022-04-06 Purac Biochem Bv Polvo de lactato y método para su preparación
CN109432038A (zh) * 2018-12-28 2019-03-08 乐普制药科技有限公司 一种含有盐酸舍曲林的肠溶片剂及其制备方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4797286A (en) 1985-11-12 1989-01-10 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
US4847092A (en) 1985-11-12 1989-07-11 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
US5112619A (en) 1985-11-12 1992-05-12 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulation
US4803076A (en) 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance
DE3700420A1 (de) 1986-12-22 1988-07-07 Efka Werke Kiehn Gmbh Fritz Tabakerzeugnis fuer die selbstverfertigung einer zigarette, insbesondere filter-zigarette
US5135947A (en) 1987-04-09 1992-08-04 Eli Lilly And Company 1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors
US4777288A (en) 1987-06-11 1988-10-11 Pfizer Inc. Process for preparing a 4,4-diphenylbutanoic acid derivative
US4792448A (en) 1987-06-11 1988-12-20 Pfizer Inc. Generic zero order controlled drug delivery system
US4839104A (en) 1987-06-11 1989-06-13 Pfizer, Inc. Process for preparing sertraline intermediates
US4971998A (en) 1987-10-22 1990-11-20 Massachusetts Institute Of Technology Methods for treating the premenstrual or late luteal phase syndrome
US4876282A (en) 1987-11-25 1989-10-24 Eli Lilly And Company 1-Phenylalkylamines as selective serotonin uptake inhibitors
US4855500A (en) 1988-05-04 1989-08-08 Pfizer Inc. Process for preparing a ketimine
US5026707A (en) 1988-05-23 1991-06-25 Eli Lilly And Company Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes
IL91398A (en) 1988-08-30 1994-05-30 Pfizer A device for the controlled release of pneumatic substances, including the active substance, surrounded by an asymmetric membrane
IL93464A (en) 1989-02-27 1996-10-16 Lilly Co Eli 2-Amino-1,2,3,4-Tetrahydronaplanin and 3 aminochromes with a transformed ring, a process for their preparation and pharmaceutical preparations containing them
US4981870A (en) 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
US4983401A (en) 1989-05-22 1991-01-08 Kinaform Technology, Inc. Sustained release pharmaceutical preparations having pH controlled membrane coatings
US5130338A (en) 1989-08-30 1992-07-14 Pfizer Inc. Method of treating chemical dependencies using sertraline
US4940731A (en) 1989-08-30 1990-07-10 Pfizer Inc. Method of treating premature ejaculation using sertraline
EP0415612B1 (en) 1989-08-30 1993-11-10 Pfizer Inc. Use of sertraline for the treatment of chemical dependencies
US4962128A (en) 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
WO1992000103A1 (en) 1990-06-28 1992-01-09 Beecham Group Plc Pharmaceutical preparations
ES2067957T3 (es) 1990-08-07 1995-04-01 Pfizer Uso de membranas polimerizadas interfacialmente en dispositivos de liberacion.
PT98628A (pt) 1990-08-09 1992-06-30 Massachusetts Inst Technology Processo de composicoes farmaceuticas a base de por exemplo sertralina
US5104899A (en) 1990-08-13 1992-04-14 Sepracor, Inc. Methods and compositions for treating depression using optically pure fluoxetine
AU658155B2 (en) 1990-11-24 1995-04-06 Beecham Group Plc Use of paroxetine for the treatment of senile dementia, or anorexia
NZ241495A (en) 1991-02-08 1994-10-26 Lilly Co Eli 2-amino-1,2,3,4-tetrahydronaphthalene and 3-aminochromane derivative, preparation and pharmaceutical compositions thereof
WO1992018005A1 (en) 1991-04-16 1992-10-29 National Institutes Of Health Method of treating trichotillomania and onychophagia
US5196607A (en) 1992-02-14 1993-03-23 Pfizer Inc. Process for preparing ketone enantiomer
ATE173159T1 (de) 1992-03-25 1998-11-15 Depomed Systems Inc Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
US5518730A (en) 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5248699A (en) 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US6440457B1 (en) 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
IE930485A1 (en) 1993-06-28 1994-12-28 Hemisphere Ltd Antidepressant agents with a rapid onset of action
US5597826A (en) 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
WO1996009047A1 (en) 1994-09-19 1996-03-28 The Du Pont Merck Pharmaceutical Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
PT768083E (pt) 1995-07-17 2003-08-29 Pfizer Sertralina para o tratamento de doentes pos-enfarte miocardico
GB9514842D0 (en) 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
IL126203A (en) 1996-03-25 2002-12-01 Lilly Co Eli A synergistic painkiller that contains olenzapine and another painkiller
ZA97976B (en) 1996-04-05 1997-08-18 Alza Corp Uniform drug delivery theraphy.
US5741807A (en) 1996-09-27 1998-04-21 Cytos Pharmaceuticals, L.P. Histidine compositions and methods for treating or preventing infectious and non-infectious diarrheas
US6590083B1 (en) 1999-04-16 2003-07-08 Ortho-Mcneil Pharmaceutical, Inc. Ketolide antibacterials

Also Published As

Publication number Publication date
JP2000514101A (ja) 2000-10-24
TNSN98125A1 (fr) 2005-03-15
KR20010014043A (ko) 2001-02-26
HRP980379A2 (en) 1999-04-30
KR100412327B1 (ko) 2003-12-31
HUP0002296A3 (en) 2001-11-28
AR015919A1 (es) 2001-05-30
NZ513456A (en) 2003-02-28
PE88699A1 (es) 1999-09-20
EA002482B1 (ru) 2002-06-27
US6517866B1 (en) 2003-02-11
SK180499A3 (en) 2001-08-06
UY25067A1 (es) 2000-12-29
NO996518D0 (no) 1999-12-28
TR199903280T2 (xx) 2000-11-21
IL133080A0 (en) 2001-03-19
CN1256085C (zh) 2006-05-17
PL337806A1 (en) 2000-09-11
AP9801281A0 (en) 1998-06-30
DZ2546A1 (fr) 2003-02-08
MY129175A (en) 2007-03-30
OA11245A (en) 2003-07-23
PA8454401A1 (es) 2000-05-24
AU739261B2 (en) 2001-10-11
EP0999830A1 (en) 2000-05-17
CO4940402A1 (es) 2000-07-24
EA199900964A1 (ru) 2000-08-28
TWI241188B (en) 2005-10-11
HK1026630A1 (en) 2000-12-22
WO1999001121A1 (en) 1999-01-14
CN1261793A (zh) 2000-08-02
AU7544998A (en) 1999-01-25
KR20040004367A (ko) 2004-01-13
HUP0002296A2 (hu) 2001-10-28
HRP980379B1 (en) 2003-04-30
AP1526A (en) 2006-01-03
IS5265A (is) 1999-11-23
CA2290966A1 (en) 1999-01-14
NO996518L (no) 2000-02-29
IL152330A0 (en) 2003-05-29
BR9810403A (pt) 2000-08-29
ID23503A (id) 2000-04-27
CA2290966C (en) 2005-12-20
NZ501251A (en) 2001-09-28
KR100446366B1 (ko) 2004-09-01
AR065827A2 (es) 2009-07-08

Similar Documents

Publication Publication Date Title
BG103915A (en) Sertraline salts and sertralin-containing batched forms with delayed release
MD1663B2 (en) Composition and methods for human sexual activity modulation and impotency treatment
CA2213339A1 (en) Method of treating adenosine depletion
BR9814389A (pt) Forma de dosagem farmacêutica revestida entérica, processo para a preparação da mesma, uso desta, pelota ou tablete encamado para a mesma, e, processos para melhorar a inibição da secreção de ácido gástrico, e para melhorar o efeito terapêutico no tratamento de distúrbios gastrointestinais associados com secreção de ácido em excesso
MX9500243A (es) Composicion de liberacion acelerada que contiene bromocriptina.
FI970747A (fi) Yhdistelmävalmiste käytettäväksi immunologisissa sairauksissa
CA2289717A1 (en) Novel therapy for constipation
MY129293A (en) The use of mmp-13 selective inhibitors for the treatment of osteoarthristis and other mmp-mediated disorders
IL120317A (en) Ciprofloxacin-hydrocortisone suspension
NZ326754A (en) The use of 2-amino-4-(4-fluorobenzylamino)-1-ethoxy-carbonylaminobenzene or salts thereof for the prophylaxis and treatment of sequelae of chronic reduced circulation in the brain in particular strokes and for neurodegenerative disorders
PL310476A1 (en) Application of lamotrigin in treating neuro-aids diseases
AU3951389A (en) The use of alpha-amino boronicacid derivatives for the prophylaxis and treatment of virus diseases
GR3034040T3 (en) CoA-IT AND PAF INHIBITORS.
NZ503169A (en) Synthesis of clasto-lactacystin beta-lactone whereupon the process relies upon a stereoselective addition of a formyl amide to an oxazoline
BG102556A (en) Orally applied pharmaceutical composition with modified release containing 5-asa, and a method for the treatment of intestinal diseases
MY104006A (en) 4-quinoline carboxylic acid derivatives useful for treating skin and muco-epithelial diseases.
MY118244A (en) Alfa-amino acid amides, preparation thereof and the therapeutical use thereof
NO179245C (no) Arylalkylestere av 4,5-dihydroksy-9,10-dihydro-9,10-diokso-2-antracenkarboksylsyre med terapeutisk aktivitet
FI891324A0 (fi) 1-metyyli-3,5,7-triatsa-1-atsoniatrisyklodekaaniyhdisteitä, menetelmä näiden yhdisteiden valmistamiseksi ja niiden käyttö mikro-organismien kontrolloimiseksi vesijärjestelmissä sekä niiden käyttö korroosionestoaineina
AP2003002905A0 (en) Sertraline salts and sustained-release dosage forms of sertraline.
IE842584L (en) Gaba-transaminase inhibitors
MY106605A (en) Compositions for the treatment of leishmaniasis
MY110416A (en) Composition for the treatment of schizophrenia.
DE69331237D1 (de) Antiatherosclerotische mittel
TH43680A (th) เกลือเชอร์ทราลีนและรูปแบบการใช้ที่มีการหน่วงการปลดปล่อยของเซอร์ทราลีน